The drugmaker posts earnings that narrowly beat expectations and raises its full-year outlook.

The drug and medical-device maker raised its forecast for the year after recording higher sales in the second quarter.

Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk ...

Johnson & Johnson JNJ on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full ...

Johnson & Johnson Q2 2026 results: 6.6% revenue growth, Pharma/MedTech strength, and dividend stability. Click for this JNJ ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Johnson & Johnson has encountered its share of troubles in recent years. Let's briefly go through the list and name some of them. The company is still dealing with thousands of lawsuits from ...

If health care industry corruption and criminality were a city skyline, it would be booming, with tower cranes and half-built skyscrapers in every direction. Among the downtown giants at the center ...

Add Yahoo as a preferred source to see more of our stories on Google. On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked ...

When most people experience an itch, they think nothing of it; a simple scratch can usually tame it. The itch experienced by people living with atopic dermatitis (AD), commonly known as eczema, is ...

On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked her parents to stay home from school, and they gave her one ...